Sean Duffy Sells 40,796 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 40,796 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $15.95, for a total transaction of $650,696.20. Following the completion of the sale, the chief executive officer owned 126,644 shares in the company, valued at $2,019,971.80. The trade was a 24.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Omada Health Trading Up 1.0%

Shares of OMDA stock opened at $15.65 on Friday. The firm has a fifty day moving average price of $16.94 and a 200 day moving average price of $19.98. The company has a market cap of $906.29 million and a P/E ratio of -62.60. Omada Health, Inc. has a 12 month low of $14.14 and a 12 month high of $28.40.

Institutional Investors Weigh In On Omada Health

A number of institutional investors and hedge funds have recently made changes to their positions in OMDA. Sanofi purchased a new position in Omada Health during the 2nd quarter worth $9,606,000. Teacher Retirement System of Texas acquired a new stake in Omada Health in the second quarter valued at about $640,000. Jennison Associates LLC purchased a new stake in Omada Health in the 2nd quarter valued at approximately $4,580,000. Emerald Advisers LLC acquired a new position in Omada Health during the 2nd quarter worth approximately $5,089,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Omada Health in the 2nd quarter valued at approximately $2,950,000.

Analysts Set New Price Targets

OMDA has been the topic of a number of recent analyst reports. Morgan Stanley set a $32.00 price objective on Omada Health in a report on Thursday, December 18th. The Goldman Sachs Group set a $29.00 price target on shares of Omada Health in a research note on Friday, January 9th. Needham & Company LLC raised their price objective on shares of Omada Health from $26.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 7th. BMO Capital Markets started coverage on shares of Omada Health in a report on Thursday, November 13th. They issued an “outperform” rating and a $27.00 target price for the company. Finally, Wells Fargo & Company initiated coverage on shares of Omada Health in a research note on Thursday, January 8th. They set an “equal weight” rating and a $17.00 price target on the stock. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $25.40.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.